Agilent Technologies (NYSE:A) Upgraded at Bank of America

Agilent Technologies (NYSE:A) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued on Thursday,Benzinga reports. The brokerage currently has a $145.00 price objective on the medical research company’s stock, down from their prior price objective of $150.00. Bank of America‘s price objective suggests a potential upside of 25.20% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Barclays reduced their price target on Agilent Technologies from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Morgan Stanley decreased their price target on Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Wall Street Zen downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen decreased their price target on Agilent Technologies from $170.00 to $157.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, UBS Group decreased their price target on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies presently has an average rating of “Buy” and an average target price of $161.07.

Agilent Technologies Price Performance

A stock opened at $115.82 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59. The firm has a market capitalization of $32.73 billion, a P/E ratio of 25.57, a P/E/G ratio of 2.42 and a beta of 1.22. The business’s 50-day moving average is $114.99 and its two-hundred day moving average is $128.79. Agilent Technologies has a 1 year low of $108.35 and a 1 year high of $160.27.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.80 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.Agilent Technologies’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Analysts anticipate that Agilent Technologies will post 5.95 earnings per share for the current fiscal year.

Institutional Trading of Agilent Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA lifted its holdings in shares of Agilent Technologies by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock valued at $1,925,064,000 after purchasing an additional 1,713,216 shares during the last quarter. State Street Corp increased its position in Agilent Technologies by 1.9% in the 4th quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after acquiring an additional 241,029 shares during the period. Wellington Management Group LLP increased its position in Agilent Technologies by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock valued at $1,203,990,000 after acquiring an additional 433,342 shares during the period. Geode Capital Management LLC increased its position in Agilent Technologies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company’s stock valued at $1,006,519,000 after acquiring an additional 25,139 shares during the period. Finally, Generation Investment Management LLP increased its position in Agilent Technologies by 10.1% in the 3rd quarter. Generation Investment Management LLP now owns 6,357,953 shares of the medical research company’s stock valued at $816,043,000 after acquiring an additional 582,093 shares during the period.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent beat Q2 expectations with adjusted EPS of $1.49 versus consensus around $1.41 and revenue of $1.83 billion versus the $1.80 billion forecast, showing solid execution and 10% year-over-year sales growth. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 profit outlook, citing strong demand for lab tools and research/diagnostic equipment, which supports the case for higher earnings ahead. Agilent raises 2026 profit forecast on strong demand for lab tools
• Positive Sentiment: Management’s updated FY 2026 guidance of $6.00-$6.10 EPS and $7.4 billion-$7.5 billion revenue came in slightly above Wall Street expectations, reinforcing confidence in continued growth. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
• Neutral Sentiment: Analyst coverage remained constructive, with RBC starting coverage at Outperform and Baird lifting its price target, which adds support but is not a direct operating catalyst. Analyst coverage updates
• Negative Sentiment: Agilent’s Q3 EPS guidance of $1.48-$1.50 was only in line with, or slightly below, estimates, which may temper enthusiasm despite the stronger full-year outlook. Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.